Other News To Note
Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said a preclinical study of its influenza DNA vaccine against the newly emergent virulent H7N9 flu virus showed that the vaccine achieved immune response levels exceeding what are considered protective levels in other common influenza subtypes.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter